Glipizide-d11 is intended for use as an internal standard for the quantification of glipizide by GC- or LC-MS. Glipizide is a hypoglycemic agent.1 It inhibits ATP-sensitive potassium (KATP) channels in primary mouse pancreatic β cells (IC50 = 6.4 nM). Glipizide induces insulin release from isolated rat pancreatic tissue with an EC50 value of 40 nM.2 Dietary administration of glipizide (5 mg/kg per day for 10 days) increases the number of insulin receptors on isolated and purified mouse liver plasma membranes.3 It reduces plasma glucose and triglyceride, but not total cholesterol, levels and increases plasma insulin levels in a rat model of diabetes induced by a high-fat diet and streptozotocin when administered orally at a dose of 5 mg/kg.4 Formulations containing glipizide have been used in the treatment of type 2 diabetes.
1.ZÜnkler, B.J., Lenzen, S., MÄnner, K., et al.Concentration-dependent effects of tolbutamide, meglitinide, glipizide, glibenclamide and diazoxide on ATP-regulated K+ currents in pancreatic B-cellsNaunyn-Schmiedebergs Arch. Pharmacol.337(2)225-230(1998) 2.Herchuelz, A., and Malaisse, W.J.Insulinotropic potency of glipizide in vitroDiabetologia309-310(1973) 3.Feinglos, M.N., and Lebovitz, H.E.Sulphonylureas increase the number of insulin receptorsNature276(5684)184-185(1978) 4.Srinivasan, K., Viswanad, B., Asrat, L., et al.Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: A model for type 2 diabetes and pharmacological screeningPharmacol. Res.52(4)313-320(2005)